Bannerbild German Brest Group

How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

03.02.2017

Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.

http://ascopubs.org/doi/abs/10.1200/JCO.2016.71.3503

News

  • 24.11.2016  Offene Stellen

    Offene Stellen

    Zurzeit suchen wir einen Clinical Data Manager (m/w) und einen Clinical Trial Coordinator (m/w). Die einzelnen Stellenbeschreibungen finden Sie in unserem Karriere-Portal.

    Mehr ...
  • 21.11.2016  GBG 75 - INSEMA

    Am 14. November 2016 wurde Amendment 4 Teil 1 der INSEMA Studie live geschaltet. Wir wünschen Ihnen einen guten Start.

    Mehr ...
  • 08.11.2016  Tailored, Dense-Dose Chemotherapy for Early Breast Cancer Does Not Result in Significant Improvement in Recurrence-Free Survival

    Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd